CC BY 4.0 · TH Open 2022; 06(04): e299-e303
DOI: 10.1055/a-1920-6224
Original Article

Apixaban Prophylactic Anticoagulation in Patients with Nephrotic Syndrome

1   Department of Nephrology and Dialysis, Hôpital Erasme ULB, Brussels, Belgium
,
Alexandre Cez
2   Department of Nephrology and Dialysis, Assistance Publique Hôpitaux de Paris, Hôpital Tenon, Paris, France
,
Karine Dahan
2   Department of Nephrology and Dialysis, Assistance Publique Hôpitaux de Paris, Hôpital Tenon, Paris, France
,
Emmanuel Esteve
2   Department of Nephrology and Dialysis, Assistance Publique Hôpitaux de Paris, Hôpital Tenon, Paris, France
,
Ismail Elalamy
3   Hematology and Thrombosis Center, Hôpital Tenon, Hôpitaux Universitaires de l'Est Parisien, Assistance Publique Hôpitaux de Paris, Faculté de Médecine, Sorbonne Université, Paris, France
4   Research Group Cancer, Haemostasis and Angiogenesis, INSERM U938, Centre de Recherche Saint-Antoine, Institut Universitaire de Cancérologie, Faculty of Medicine, Sorbonne University, Paris, France
5   Sorbonne Université, INSERM UMRS1155, Hôpital Tenon, Paris, France
6   Department of Obstetrics and Gynaecology, The First I.M. Sechenov Moscow State Medical University, Moscow, Russia
,
Jean Jacques Boffa
2   Department of Nephrology and Dialysis, Assistance Publique Hôpitaux de Paris, Hôpital Tenon, Paris, France
5   Sorbonne Université, INSERM UMRS1155, Hôpital Tenon, Paris, France
,
Eleonore Ponlot
7   Departement of Nephrology and Dialysis, Grand Hôpital de Charleroi GHDC, Charleroi, Belgium
› Author Affiliations
Funding None.

Abstract

Background Nephrotic syndrome (NS) is associated with an increased risk of thromboembolic events (TEs), due to hemostatic derangements. The use of direct oral anticoagulants (DOACs) in the prevention of TE has not been studied intensively in patients suffering from NS.

Methods The method included retrospective analysis of consecutive incident patients with NS due to glomerular disease, receiving apixaban for thromboprophylaxis. It is an uncontrolled, single-center study.

Results We identified 27 patients treated with apixaban for the prevention of TEs, in the context of NS. During follow-up, apixaban minimal blood concentration (trough level; Cmin) and maximum blood concentration (Cmax) levels were measured. The mean duration of the anticoagulant treatment was 153 days (±132). Patients were followed for a mean of 14.7 months (±8.4) since the introduction of apixaban. Three patients had a TE at the time of NS diagnosis. Two patients had pulmonary embolism (PE) and one patient presented a stroke in a lupus membranous nephropathy context. One patient developed PE approximately 2 months after the introduction of apixaban treatment. No minor or major bleeding events were noticed.

Conclusion The present study shows that patients, suffering from severe NS under anticoagulant therapy with apixaban had a reduced risk of venous and arterial TEs compared with patients previously described in the literature, without increased risk of bleeding.

Ethics Approval and Consent to Participate

Approval of ethical committee was not required for this retrospective, and observational study according to Helsinki law and French institutional committee. All patients consented to participate in research studies related to the NS.


Consent for Publication

Not applicable.


Availability of Data and Materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.


Authors' Contributions

E.P. created the dataset. T.V.M. completed and statistically analyzed the dataset and drafted the manuscript. J.J.B. and I.E. revised the manuscript. All authors read and approved the final version of the manuscript.




Publication History

Received: 15 December 2021

Accepted: 25 July 2022

Accepted Manuscript online:
08 August 2022

Article published online:
07 October 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Kerlin BA, Ayoob R, Smoyer WE. Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. Clin J Am Soc Nephrol 2012; 7 (03) 513-520
  • 2 Barbour SJ, Greenwald A, Djurdjev O. et al. Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int 2012; 81 (02) 190-195
  • 3 Gyamlani G, Molnar MZ, Lu JL, Sumida K, Kalantar-Zadeh K, Kovesdy CP. Association of serum albumin level and venous thromboembolic events in a large cohort of patients with nephrotic syndrome. Nephrol Dial Transplant 2017; 32 (01) 157-164
  • 4 Ismail G, Mircescu G, Ditoiu AV, Tacu BD, Jurubita R, Harza M. Risk factors for predicting venous thromboembolism in patients with nephrotic syndrome: focus on haemostasis-related parameters. Int Urol Nephrol 2014; 46 (04) 787-792
  • 5 Mahmoodi BK, ten Kate MK, Waanders F. et al. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation 2008; 117 (02) 224-230
  • 6 Kelddal S, Nykjær KM, Gregersen JW, Birn H. Prophylactic anticoagulation in nephrotic syndrome prevents thromboembolic complications. BMC Nephrol 2019; 20 (01) 139
  • 7 Medjeral-Thomas N, Ziaj S, Condon M. et al. Retrospective analysis of a novel regimen for the prevention of venous thromboembolism in nephrotic syndrome. Clin J Am Soc Nephrol 2014; 9 (03) 478-483
  • 8 Rostoker G, Durand-Zaleski I, Petit-Phar M. et al. Prevention of thrombotic complications of the nephrotic syndrome by the low-molecular-weight heparin enoxaparin. Nephron J 1995; 69 (01) 20-28
  • 9 Sexton DJ, de Freitas DG, Little MA. et al. Direct-acting oral anticoagulants as prophylaxis against thromboembolism in the nephrotic syndrome. Kidney Int Rep 2018; 3 (04) 784-793
  • 10 Han THC, Thet Z. Warfarin vs. new oral anticoagulant in primary adult nephrotic syndrome associated venous thromboembolism. Nephrology (Carlton) 2017; 22: 64
  • 11 Matta A, Elenizi K, AlHarthi R, Moussallem N, Elhajjaji N, Lhermusier T, Carrié D. A Case of Isolated Unilateral Right Renal Vein Thrombosis Associated with Bilateral Pulmonary Embolism Treated with Rivaroxaban a Direct-Acting Oral Anticoagulant. Am J Case Rep 2019 Aug 6; 20:1152–1154. Doi 10.12659/AJCR.916638 PMID: 31383838; PMCID: PMC6691838
  • 12 Zhang L, Zhang H, Zhang J, Tian H, Liang J, Liu Z. Rivaroxaban for the treatment of venous thromboembolism in patients with nephrotic syndrome and low AT-III: a pilot study. Exp Ther Med 2018; 15 (01) 739-744
  • 13 Dupree LH, Reddy P. Use of rivaroxaban in a patient with history of nephrotic syndrome and hypercoagulability. Ann Pharmacother 2014; 48 (12) 1655-1658
  • 14 Ramos-Esquivel A. Monitoring anticoagulant therapy with new oral agents. World J Methodol 2015; 5 (04) 212-215
  • 15 Byon W, Garonzik S, Boyd RA, Frost CE. Apixaban: a clinical pharmacokinetic and pharmacodynamic review. Clin Pharmacokinet 2019; 58 (10) 1265-1279
  • 16 Granger CB, Alexander JH, McMurray JJV. et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
  • 17 Agnelli G, Buller HR, Cohen A. et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (09) 799-808
  • 18 Agnelli G, Buller HR, Cohen A. et al; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368 (08) 699-708
  • 19 Lionaki S, Derebail VK, Hogan SL. et al. Venous thromboembolism in patients with membranous nephropathy. Clin J Am Soc Nephrol 2012; 7 (01) 43-51